We are currently conducting the following trials :
.png)
Colonoscopy is a direct visualization technique which allows both visualization and instrumentation of the entire colon under optimized conditions. It was first recommended in 1997 as a screening test for individuals reaching their 50th year. It is unique amongst screening modalities in its ability to detect, biopsy, and contemporaneously treat suspected pre-malignant and malignant lesions. Its use as a screening tool is recommended by all national gastroenterology and cancer societies of note in Europe and North America7. The efficacy of colonoscopy was established in a large multicenter study, the National Polyp Study, which showed a 76-90% reduction in CRC incidence 5.
.png)
CD can be broadly defined as an inflammatory disease affecting any part of the GI tract from mouth to anus, though it commonly affects the ileum and colon. Importantly, CD is characterized by the involvement of the entire gut wall, with an anatomical location in any part of the GI tract and a tendency to present complications such as fistulae and strictures. There are several theories as to contributing factors for CD pathogenesis. The complex etiology includes an interplay between genetics, bacteria, and environmental factors.
This is a decentralized study to evaluate the efficacy and safety of study inhaler taken as needed, for up to 12 months. Participants 12 years of age and older with asthma will be recruited with all visits conducted virtually.
.png)
A migraine day is defined as a calendar day (12:00am to 11:59pm) in which the subject experiences a migraine attack that starts, ends or recurs within 24 hours and lasts for ≥1 hour (if untreated) or ≥30 minutes (if interrupted with rescue medication). Pain persisting for more than 1 calendar day (≥24 hours) after initial onset will be considered as a new, distinct headache day. Monthly migraine days is defined as the number of migraine days within 28 days or 4 weeks.
This pediatric study is intended to confirm safety in infants between 12 weeks to < 12 years of age and to bridge immunogenicity between infants/children and adults (> 18 years of age) enrolled in adult studies. It is necessary to demonstrate non-inferiority of the induced immune response in infants and children compared with that in adults to infer vaccine effectiveness in this age group.
If you’d like to register for any of the above studies, click the 'Join Our Patient List' button to register. If you have any questions, please feel free to email or give us a call:
info@clinicalresearchofcalifornia.com | 925-705-7346info@clinicalresearchofcalifornia.cominioiiiiiinfo@clinicalresearchofcalifornia.cominfo@clinicalresearchofcalifornia.com
.png)